@jhrheumatology data on ESRD in Lupus Nephritis, Dr. Michelle Petri. #ACR21 Debate ▶️ 20% risk of renal failure in 20 years is way too high ▶️ C3 strongest predictor, dsDNA also seen ⭐️⬇️ complement, ⬆️dsDNA in lupus nephritis suggests Belimumab is good agent for LN @Rheumnow https://t.co/ewLAxMgTT0

#ACR21 @RheumNow Abst#0359 by Garrido-Cumbrera et al. has mapped out the journey from symptom onset to diagnosis of axSpA across 13 European countries.

Before the Great Debate: Next step for Lupus Nephritis? #ACR21 @Rheumnow

Abstract 0095 Barbhiaya et al examined risk factors for 'Long Haul' COVID-19 in Rheumatology Outpatients in NYC #ACR21 @RheumNow

Phase 2 German study demonstrates superiority of TCZ vs PBO in FMF. SAA levels only normalized in TCZ treated patients. Interesting concept that needs to be replicated in larger trials. Abs 0193 #ACR21 #RheumNow @RheumNow https://t.co/awqOpwg3gH https://t.co/lGzYglnkyM

• Tocilizumab for the Treatment of Familial Mediterranean Fever – a Randomized, D…

Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm. In biologic arm 14% IL-1i switched to IL-6i, 0% from IL-6i to IL-1i. 50%GC/MTX eventually initiated biologic therapy . 57% of pts d/cGC use, and 75% had cJADAS-10 score ≤ 2.5 https://t.co/vH0AnocTr2

Data science for the dumbs. Very informative talk from Dr Jamie Collins! Surely helpful for me. A good way to decide on the best supervised methods for data analysis in machine learning is to separate according to our goal: to explain or to predict? #ACR2021 @RheumNow https://t.co/J0j6VMkoTV

#ACR21 2nd abstract #0381 from #DESIR cohort by @ElenaNikiUK: •High disease activity & decreased function assoc w/ greater #WorkDisability •Not enough to just treat the disease! Need holistic approaches to improve function, QoL & work outcomes. @RheumNow https://t.co/jIs3Oj7nbJ

• How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Ax…

Completely new one for me, Dr Taniguchi presenting on using ear ultrasound to diagnose and monitor disease activity in relapsing polychondritis. Appears useful, I suspect in clinical practice more so for diagnosis. Abstr#0169 #ACR21 @RheumNow https://t.co/PLJtkYkP3A

@jhrheumatology Dr. Petri at #ACR21 Great Debate. Safety issues with Voclosporin: 1) Nephrotoxicity 2) Infection 3) CV Risk Factors 4) Malignancy 5) Neurologic toxicity 6) Osteoporosis 7) Drug interactions 8) Deaths 9) Pregnancy contraindication @RheumNow https://t.co/wjluivmKNt

#ClinicalPearl. Pts have no preference btwn phone or video telemedicine. You can get calls more easily in PJs, technology of internet may be difficult for elderly, hearing impaired & rural with poor internet bandwidth so I would’ve guessed phone was preferred @RheumNow #abst0112 https://t.co/1F4HH9nXB8

• Aurelie Najm on Twitter: "💻 Telemedicine: would you rather have a telephon…

RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Is holding MTX during breastfeeding overblown? @MotherToBaby data showed that infants get 0.4% of mom’s dose 24 hrs post-MTX dose. Skip breastfeeding 1 day post-MTX may be safe. Consider monitoring infant CBC. Studies needed to follow infants longitudinally #ACR21 @rheumnow https://t.co/ikJvkk5BjI

#ACR21 Abst#0170: ↑ epicardial adipose tissue volume predicts new coronary plaque development in the following RA patients: ⋆ <10 yrs dz (OR 5.75) ⋆ 1 cardiac risk (OR 3.4) ⋆ statin < 1 yr (OR 3.3) ⋆ w/o calcification at b/l (OR 2.65) @Rheumnow https://t.co/tnyWRVSger https://t.co/uhak4kdbll

• Direct and Conditional Effects of Epicardial Adipose Tissue Volume on Coronary …

Interesting study on 5yr CV event risk in early #rheumatoidarthritis pts who received T2T mgt shows no difference in CVE risk in ERA grp vs control ERA cohort: > Longer remission = protective for CVE > ⬆ HAQ = predictive of CVE Tighter control, ⬇ CVEs @RheumNow #ACR21 abs0282 https://t.co/GG7HPvWd0r